Objectives: To measure uptake and disposal kinetics and absolute absorption of vitamin K 1 using two stable isotope-labelled forms of vitamin K 1 . Subjects: Ten subjects (nine women and one man) aged between 22 and 31 years, with a mean (7standard deviation) body mass index of 22.572.4 kg/m 2 . Subjects took capsules containing 3 mg of methyl-13 C vitamin K 1 , three times a day for six days to reach a steady state for plasma vitamin K 1 isotopic enrichment. On day seven, subjects were given an intravenous dose of Konakion MM to measure disposal kinetics and at the same time, a capsule containing 4 mg of ring-D 4 vitamin K 1 to measure absorption. Plasma vitamin K 1 concentration was measured by high-performance liquid chromatography and isotopic composition by gas chromatography mass spectrometry. Results: The disposal kinetics of the intravenous dose of vitamin K 1 were resolved into two exponentials with half-times of 0.22 (70.14) and 2.66 (71.69) h. Absorption of oral, deuterated vitamin K 1 was 13 (79) %. Conclusions: Two-compartmental kinetic parameters observed in this study are similar to those obtained previously using radioactive tracers, but there may be additional slow-turnover body pools acting as stores of vitamin K 1 . The kinetic parameters determined from the intravenous dose allowed determination of the absolute absorption of vitamin K 1 from a bolus oral dose.
Introduction
Vitamin K is a fat-soluble vitamin required as a cofactor in the post-translational carboxylation of glutamic acid to g-carboxyglutamic acid in vitamin K-dependent (VKD) proteins. VKD proteins were originally discovered as crucial in the control and regulation of blood coagulation (for example, prothrombin, factors II, VII, IX and X, and proteins C and S), but more recent evidence suggests a wider role for vitamin K in human health. In particular, low vitamin K intake has been associated with low bone mineral density (Booth et al., 2003a) and an increased fracture risk (Feskanich et al., 1999; Booth et al., 2000) and low plasma vitamin K status has been associated with an increased prevalence of osteoarthritis (Neogi et al., 2006) . Evidence is also emerging for a benefit of increased vitamin K intake and status in reducing vascular calcification via the VKD protein, matrix Gla protein (Jie et al., 1995; Schurgers et al., 2001; Berkner and Runge, 2004) .
It is therefore possible that current recommended intakes, although adequate to maintain full carboxylation of vitamin K-dependent coagulation proteins (Suttie et al., 1988) , are insufficient to maintain other VKD proteins, including osteocalcin, in the fully carboxylated state (Binkley et al., 2000 (Binkley et al., , 2002 Booth et al., 2003b) . Partly in recognition of this, recommended intakes in the United States have recently been increased to 90 and 120 mg/day for women and men, respectively (Institute of Medicine, 2001) . There is no recommended intake for vitamin K in the United Kingdom, although a guideline intake of X1 mg/kg body weight/day was set 15 years ago (Department of Health, 1991) .
In Western populations, vitamin K 1 (phylloquinone) is the primary dietary form of vitamin K (Schurgers et al., 1999) . Vitamin K 2 from the diet is likely to only be important to vitamin K status in populations that consume high levels vitamin K 2 -rich foods, such as natto. The potential contribution of vitamin K 2 from colonic microbes to vitamin K status is an area of some debate, largely because of an uncertainty over their bioavailability that is determined both by release from bacterial membranes and uptake from the gut (Schurgers et al., 1999) . Vitamin K 1 is found in a wide range of foods, but green leafy vegetables contain the highest amounts of the vitamin and are thus considered the main dietary source (Thane et al., 2006) . However, there is uncertainty over the extent of vitamin K 1 availability from the diet.
There have been several studies to measure relative availability from measurements of the area under the plasma response curve following oral doses from a variety of sources, including some designated as standards such as Konakion (Gijsbers et al., 1996; Booth et al., 1999; Garber et al., 1999; Booth et al., 2002) , but the results are difficult to compare because a variety of doses, ranging from those typical of a high daily intake but fed in a single meal, to quantities at least an order of magnitude higher, have been used and experimental duration has varied from hours to days. It is possible, however, to make a general conclusion that for some meal types vitamin K 1 absorption is very poor, and that absorption of vitamin K 1 from vegetables is lower than absorption from a standard form (Gijsbers et al., 1996; Garber et al., 1999; Schurgers and Vermeer, 2000; Booth et al., 2002) .
Data from these studies are study-specific, thus techniques to measure absolute absorption may provide more meaningful data and allow comparisons between studies. In a balance study, the difference between a large (1 mg) oral dose and faecal losses indicated a minimal value of 40-50% (Shearer et al., 1970) . However, this value was later adjusted upwards to a maximum of 80% based on the biliary excretion of metabolites (Shearer et al., 1974) .
To measure absolute vitamin K 1 absorption directly, an understanding of the kinetics of both uptake and disposal is required. Radioactive tracers have been used to explore the kinetics of vitamin K 1 metabolism, but early investigations (Shearer et al., 1970 (Shearer et al., , 1972 (Shearer et al., , 1974 Shepherd et al., 1977) were restricted both by a low specific activity of the tracer dose and the lack of a suitable methodology for the analysis of vitamin K 1 concentrations in plasma. More recently, Olson et al. (2002) performed experiments that used physiological levels of radiolabelled vitamin K 1 of much higher specific activity, with high-performance liquid chromatography (HPLC) for quantitative measurements, and obtained kinetic data substantially different from those obtained previously (Olson et al., 2002) .
Stable isotope tracers have a number of advantages over radiolabelled compounds. Firstly, they are not a source of ionizing radiation and are therefore suitable for use in human studies; secondly, with gas chromatography mass spectrometry (GC/MS), it is possible to positively identify the compound of interest by its mass spectrum while at the same time measuring tracer:tracee molar ratios, and finally, it is possible to simultaneously use more than one tracer (oral and intravenous) to separate the kinetics of absorption and metabolism (Matthews and Bier, 1983; Dainty, 2001; Stellaard, 2005) .
In this study, we have investigated the use of two stable isotope labelled species to measure vitamin K 1 kinetics from an intravenous (i.v.) dose and, simultaneously, quantify absorption of a 4 mg oral dose of vitamin K 1 .
Methods

Subjects
Ethical permission for the study was obtained from the Cambridge Local Research Ethics Committee and written consent was obtained from all subjects. A total of 10 healthy, non-smoking subjects were recruited (nine women and one man), aged 27.073.4 years, with weight of 61.0710.7 kg, and body mass index of 22.572.4 kg/m 2 (mean7standard deviation (s.d.)).
Labelled vitamin K 1
Two stable isotope-labelled forms of vitamin K 1 , methyl-13 C and ring-D 4 , were synthesized by ARC Laboratories (Apeldoorn, The Netherlands). Isotopic purity for the two stable isotope-labelled species, measured by GC/MS in our laboratory, was greater than 98%. The relative molar masses were 599 and 602 Da for the 13 C-and ring-D 4 -labelled forms, respectively. Stock solutions of about 40 and 14 mg ( 13 C and ring-D4, respectively) per 50 ml ethanol were prepared and stored at À181C. For the doses given to the subjects, appropriate volumes of the standard solution were added to groundnut oil to supply 3 mg (6.7 nmol) of 13 C-labelled and 4 mg (8.9 nmol) ring-D 4 vitamin K 1 in 0.5 ml of oil. Ethanol was evaporated from the oil by heating at 351C under N 2 with a Pierce Reacti-therm heating block and Reacti-vap evaporator (Perbio Science, Erembodegem, Belgium). After vortexing for 1 min, 0.5 ml aliquots of groundnut oil containing vitamin K 1 were transferred to gelatine capsules (kindly provided by Capsugel, Colmar, France). Capsules were prepared fresh for each subject and stored, refrigerated, in amber medicine bottles. Concentration of vitamin K 1 in oil was confirmed by extraction and analysis by HPLC.
Intravenous dose
To prepare the dose for i.v. injection, 100 ml of Konakion MM (Roche Products Ltd, Welwyn Garden City, UK) from a sealed glass ampoule was diluted to the required concentration in 5% glucose in saline to provide either 30 mg (66.7 nmol) or 6 mg (13.3 nmol) in 5 ml glucose-saline. Based on previously published kinetics and expected absorption of the oral doses, the first four subjects were given a 30 mg i.v. dose. However, analysis of these samples revealed a lower than expected isotopic enrichment after the initial loading, and the remaining six subjects were given a 6 mg i.v. dose.
Experimental protocol
At the start of the study, each subject was provided with 18 capsules containing 13 C-labelled vitamin K 1. Subjects were asked to take three capsules per day with food for six days.
On the mornings of days five, six and seven, subjects were asked to attend the volunteer suite at Human Nutrition Research having fasted overnight. On days five and six, blood samples were taken by venepuncture to establish the plateau isotopic composition of plasma vitamin K 1 . On day seven, an indwelling cannula was inserted into each forearm, one for dosing and one for blood sampling, and two baseline blood samples were collected into 9 ml ethylenediamine tetraacetic acid S-monovettes (Sarstedt Ltd, Leicester, UK). An i.v. dose of vitamin K 1 as Konakion MM was then administered, and the cannula flushed with 10 ml of saline. Simultaneously, the subject took the prepared oral dose of ring-D 4 vitamin K 1 . The dosing cannula was removed after 30 min. A small meal (two slices of toast with sunflower spread and jam) was provided after 3 h and water was permitted throughout the study. Blood samples (9 ml) were collected at 2, 5, 10, 20, 30, 40, 50, 60 and 90 min and then at 2, 3, 4, 5 and 6 h post dose. Samples were stored on ice and protected from light; within 1 h, they were centrifuged at 41C for 20 min at approximately 2000 g. Plasma was stored at À701C until analysis.
Quantitative analysis
Total plasma vitamin K 1 was measured by HPLC (Wang et al., 2004) . Long-term reproducibility of quality control plasma samples was assessed by their analysis in parallel with the unknowns to ensure the quality assurance in routine analysis. Intra-assay precisions coefficient of variation (CV) of quality control plasma samples of three concentrations of vitamin K 1 (means: 0.4, 1.4 and 3.4 nmol/l) were 5.2% (n, 6), 8.2% (n, 6) and 3% (n, 12), respectively. Inter-assay precision was 16.0% (n, 22), 12.0% (n, 21) and 8.1% (n, 15), respectively.
Isotope ratio analysis
Isotope ratio measurements of vitamin K 1 in plasma were performed by GC/MS after extraction and derivatization as described previously (Jones et al., 2006) . Briefly, sample extraction and clean up was achieved by enzyme hydrolysis with lipase and cholesterol esterase, deproteination with ethanol, extraction with hexane and solid-phase extraction. Isotopic composition was determined in the pentafluoropropionyl derivative of vitamin K 1 .
Analysis was performed on an Agilent GC/MS 5973N inert system (Agilent Technologies, Stockport, UK) comprising a 6890 GC with autosampler and equipped with on-column injection. The chromatography used a DB5-MS fused-silica capillary column (15 m Â 0.25 mm i.d., 0.25 mm film thickness). Samples were injected directly onto a guard column of deactivated fused silica (40.5 m length, 0.53 mm i.d.) connected via a zero dead volume assembly to the analytical column. Helium was used as the carrier gas with a flow rate of 1.2 ml/min operating in constant flow mode. Injection volumes were between 1 and 2 ml. Oven conditions were 601C for 2 min, ramped at 301C/min to 3251C, an isothermal hold of 2 min, followed by temperature increase of 401C/min to 3501C, and finally held for 5 min to ensure removal of any interfering compounds. The mass spectrometer was operated in electron ionization mode, with an electron energy of 70 eV, source temperature of 2301C and quadrupole temperature of 1501C. Ions 598.4-602.4 m/z (M to M þ 4) were monitored in selected ion monitoring and high-resolution mode. Each sample was measured in triplicate and isotopomer ratios (R) were calculated using the fitting methods of Bluck and Coward (1997) from the raw data generated by the GC/MS.
Calculations
Uptake kinetics of i.v. dose. The mole fraction of the injected material (x) in the sampled pool was calculated as
where the subscripts refer to measurements made before the i.v. dose (0), after it (t) and in the i.v. dose itself (u). The plasma response to the oral dose is a consequence of absorption, distribution and disposal. To separate these terms, disappearance of the unlabelled i.v. dose, given after loading with 13 C-labelled vitamin K 1 , was used to define the system's characteristics, that is, the pool sizes Q (mole) and rate constants, k (h À1 ) derived using classic methods from the slopes and intercepts of exponential disappearance (Shipley and Clark, 1972) . From visual inspection of the logarithmically transformed curves it was clear that a single compartment model was insufficient, and that it was unlikely that the curve could be satisfactorily resolved into the sum of three exponentials. Therefore, a two-exponential (and hence two-compartment) approach was adopted. The isotopic data to describe the disposition of vitamin K 1 were fitted to a two-compartment model having all external input and output (k 01 ) from the sampled (plasma) pool of size (Q 1 ), and exchange between it and a remote compartment (Q 2 ) defined in terms of k 21 (to 2 from 1) and k 12 (to 1 from 2). These combine to give two exponential terms for the disappearance of the i.v. dose. Thus, initial estimates Q 1 , k 21 , k 12 and k 01 were used to generate the coefficients of the exponentials for comparison with observed values. The advantages of calculating kinetic parameters from first principles, rather than using commercial packages are flexibility in fitting the model to the data and a full understanding of the assumptions and calculations on which the parameters are based. The initial estimates for Q 1 , k 21 , k 12 and k 01 were then adjusted with the solver function in Excel (Microsoft, Seattle, WA, USA) to minimize the differences between the predicted and observed data using non-linear methods. The corresponding T 1/2 were calculated by
where g is the slope of the corresponding exponential.
Absorption of oral dose
To calculate absolute absorption, the input, I (nmol/h) was calculated from the characteristics of the oral dose obtained from the ring-D 4 isotopomer data (R M þ 4 ) by deconvolution using the rate constants (k 01 , k 21 and k 12 ) obtained from the i.v. dose. Using * to denote this labelled material and/the input (nmol/ h), the equations are:
As we had limited data points over the period of absorption, a smooth curve was fitted to the observed Q 1 *(t) data (deuterated material in the plasma) by regression. Rather than adopting a polynomial to describe the observations, a cubic spline (a curve with continuous first and second derivatives) was used. Smoothing was achieved by relaxing the formal least-squares requirement by the addition of a term quantifying the 'roughness' of the fitted curve. This 'roughness penalty approach' (Green and Silverman, 1994) is an established method that produces a compromise between fitting noisy data exactly and minimizing the number of inflections in the fitted curve. Q 2 *(t) (deuterated material in the non-sampled pool) was obtained from Equations. 1 and 2 iteratively using Euler's method (http:// www.swarthmore.edu/NatSci/echeeve1/Ref/NumericInt/Euler1. html). Cumulative absolute absorption was calculated from the extrapolated curve by integration of input (I(t)).
Statistics were performed in SPSS (v.11) (SPSS Inc., Chicago, IL, USA).
Results
There were no significant differences between the HPLC data or Figure 1 shows the observed data points and modelled curves for all subjects combined, of both the clearance of the i.v. dose, and absorption of the oral dose of vitamin K 1 . Individual kinetic parameters (k 01 , k 21 , k 12 , Q 1 , Q 2 and T 1/2 for the fitted exponentials) are shown in Table 1 Vitamin K 1 kinetics and absorption measured using stable isotopes KS Jones et al significant differences between the kinetic parameters obtained with either the 6 or 30 mg i.v. dose as determined using the Mann -Whitney test. The root mean square (RMS) error and R 2 value can be used to validate the model and to assess the model's ability to describe the observed values. For the chosen model, the RMS error was 0.038 (fraction of the i.v. dose) and the average R 2 for the 10 individual models was 0.9843. To detect for any systematic errors in the model, the residuals (differences) between the modelled and observed values were calculated and plotted against time (Figure 2 ). The plot of residuals vs time are reasonably symmetrically scattered around zero. At each time point, the s.d. for mean time point residuals overlap zero and suggests that the model has a reasonable fit to the observed data. Absorption of the oral ring-D 4 dose of vitamin K 1 was calculated to include the disposal kinetics established from the i.v. dose. Total absorption was estimated as 13% of the administered oral dose. Individual absorption values and the time that deuterated vitamin K 1 concentration peaked in the plasma are shown in Table 2 .
Discussion
The main purpose of the present study was to investigate the utility of stable isotope techniques to simultaneously define the kinetics of vitamin K 1 metabolism and measure the extent to which oral doses are absorbed. For a kinetic experiment, the tracer needs to be distinguishable from endogenous tracee. In a typical dual stable isotope technique, one labelled form of a vitamin is given orally, and the second intravenously. However, labelled forms of vitamin K 1 suitable for i.v. administration are not easily available. To solve this problem, a novel approach was taken whereby subjects were given 13 C-labelled vitamin K 1 in capsule form for six days, with the aim of reaching a steady state for plasma vitamin K 1 13 C enrichment. Although the subsequent i.v. dose was unlabelled, the monitoring of tracer:tracee ratios to measure i.v. disappearance and calculate kinetics provided greater accuracy than measuring concentration of vitamin K 1 alone. Furthermore, the use of tracer:tracee ratios to measure kinetics also allowed the simultaneous measurement of vitamin K 1 Vitamin K 1 kinetics and absorption measured using stable isotopes KS Jones et al absorption since the two physiological processes (absorption and uptake) could be separated.
Previous work to measure vitamin K 1 kinetics has used radiolabelled compounds and the characteristics of the system expressed in terms of the half-times of two exponentials (T 1/2(fast) and T 1/2(slow) ) fitted to curves for the disappearance of plasma radioactivity, to varying degrees identified as associated with vitamin K 1 . The average values of the corresponding parameters found in the present experiments most closely resemble the values obtained by Shearer et al. (1972 Shearer et al. ( , 1974 , Shepherd et al. (1977) and Bjornsson et al. (1979) rather than those more recently reported by Olson et al. (2002) (see Table 3 ).
In the present experiments, because MS was used, the kinetic data were produced from isotopic enrichment unambiguously associated with vitamin K 1 . In the case of Olson et al. (2002) , even though the dose levels of vitamin K 1 given were genuinely tracer quantities, no measurements were made before 10 min post dose and only plasma radioactivity was measured. In these circumstances, it would be difficult to detect the fast exponential component observed in this study and the others cited in Table 3 , and later time points are likely to represent the increasing presence of radioactivity in circulating vitamin K 1 metabolites. The work of Shearer et al. (1972) showed that at 7-8 h post dose, water-soluble and lipid-soluble radioactivity were about equal, with the water-soluble component double the lipid component at 24 h. Thus, while the high specific activity material used in Olson's study provided the theoretical possibility of seeing a slow exponential component, interpretation in terms of vitamin K 1 turnover should be treated with caution.
The isotopic data have also been interpreted on the basis of a simple two-compartment model in an attempt to provide values for total body pool size (Q 1 þ Q 2 ). However, our estimate of total body pool size (5.1 nmol) is low in comparison to values (222 nmol) estimated from direct analysis of tissues (Olson et al., 2002) . While Olson's kinetic studies indicated body pool sizes of 1.3-2.7 nmol/kg (equivalent to 93-189 nmol for a 70 kg person), these data should be treated with caution because body pool size was determined via the approximation that pool size can be calculated from the intercept of a terminal exponential in kinetic studies where the correspondence of tracer radioactivity to vitamin K 1 was not established. The terminal exponential likely represents the disappearance of not only vitamin K 1 but also its metabolites. In the present study, Q 2 is calculated using the parameters Q 1 , k 12 and k 21 . The modelled size of pool 1 (Q 1 ) is similar to values for the plasma pool size calculated from vitamin K 1 concentration and approximate plasma volume and suggests that the low modelled Q 2 is not related to modelled Q 1 . A possible explanation is the existence of the third body pool connected to pool 1 to which uptake is indistinguishable from uptake to pool 2, but that has little or no route back to pool 1. As a result, it would not be observed in this study. The presence of additional vitamin K 1 body pools acting as sinks or recirculating vitamin K 1 to the plasma at rates insufficient to be detected in the present experiments is supported by direct analysis of vitamin K 1 in liver (Shearer, 1988) and bone (Hodges et al., 1993) . Chylomicron remnants are the primary vehicle for newly absorbed vitamin K 1 and are removed from the circulation by both liver and bone. The uptake of vitamin K 1 in chylomicron remnants and subsequent g-carboxylation of osteocalcin in osteoblasts has recently been demonstrated (Niemeier et al., 2005) and it is possible that once internalized in osteoblasts, intact vitamin K 1 is not released into the circulation. A potential pathway for the exit of vitamin K 1 from liver is in very-low-density lipoproteins (VLDL) as evidenced by the post-prandial appearance of vitamin K 1 in low-density lipoproteins (LDL) (Lamon-Fava et al., 1998; Schurgers and Vermeer, 2002; Erkkilä et al., 2004) . Further investigation of the existence of additional body pools may be feasible by increasing the initial enrichment produced by the 13 C-labelled dose by giving more material for longer periods and by continuing experiments for a longer time after the i.v. injection.
The foregoing reservations about the ability of the model to fully describe vitamin K 1 disposition within the body do not however invalidate the usefulness of the method in providing a description of the impulse response to a small, physiologically realistic dose typical of what might be consumed in a single meal (4 mg), or to the measurement of the amount of it that was absorbed. The most commonly used current method to measure relative availability is to estimate the area under the plasma vitamin K 1 response curve to the vitamin given in standard and test forms. It is possible that the low levels of absorption found in the present experiments are a consequence of the form in which the dose was given either through the absence of a test meal or incomplete release of vitamin K 1 from the capsule, although previous studies investigating vitamin K 1 and E have used similar capsules and have not reported lower than expected absorption (Suttie et al., 1988; Jeanes et al., 2004) . The earlier estimate of up to 80% absorption was obtained when the standard vitamin K 1 dose was provided in milk with a meal of bread and cheese (Shearer et al., 1970; Shearer et al., 1974) .
Other attempts to obtain information on vitamin K 1 absorption with the stable isotopically labelled vitamin are restricted to three studies reporting data from intrinsically labelled broccoli (Dolnikowski et al., 2002; Erkkilä et al., 2004) and kale (Kurilich et al., 2003) . For the absorption of 70 mg of vitamin K 1 from kale, Kurilich et al. (2003) report a value of 7% absorption, based on the amount of dose in the plasma at the time of peak vitamin K 1 concentration.
A caveat to this, and any study involving the use of vitamin K prepared for intravenous injection could be potential differences in the metabolic handling of the oral and intravenous doses of vitamin K 1 . Absorption of vitamin K 1 , as with other fat-soluble vitamins, occurs through the formation of micelles in the presence of bile salts in the gut lumen. Once internalized in the enteroctye, vitamin K is packaged into chylomicrons and enters the circulation via the lymph (Shearer et al., 1974) . Subsequent to chylomicron metabolism and chylomicron remnant uptake, plasma transport of vitamin K takes place primarily in VLDLs (Lamon-Fava et al., 1998; Schurgers and Vermeer, 2002; Erkkilä et al., 2004) . Due to the highly lipophilic nature of vitamin K, it is necessary to have carrier to enable i.v. injection. The i.v. form, Konakion MM, is a pharmaceutical preparation of vitamin K 1 in which the vitamin is solubilized in mixed micelles formulated from glycocholate and lecithin. Upon injection, the vitamin K 1 is rapidly released and it is reported that the mixed micelles do not influence the behaviour of the vitamin. Kinetic results from an i.v. dose of Konakion MM (Soedirman et al., 1996) are similar to those that have used other formulations and radiolabelled compounds, as described previously. There are insufficient data to conclude that Konakion MM is, or is not metabolized differently to absorbed, oral vitamin K 1 . However, differences may exist between vitamin K 1 uptake from chylomicron remnants and the Konkaion MM formulation because the latter lack any of the proteins that lead to lipoprotein uptake, for example, apolipoprotein E. In an attempt to quantify any differences between metabolism of the two forms, the T 1/2 of disappearance of the deuterated oral dose of vitamin K 1 was estimated from the absorption curves. The terminal slope was calculated by regression of the plasma concentration of deuterated vitamin K 1 in the final two or three data points for each subject. The T 1/2 was calculated from division of 0.693 by the slope. Values were obtained for nine of the 10 subjects, and the average T 1/2 was 2.39 h, not significantly different (calculated by paired Student's t-test) from 2.66 h derived from the i.v. kinetics (P ¼ 0.78), and suggests that there was no difference in the metabolic handling of the oral and i.v. forms of the vitamin.
In the calculations, absorption is calculated on the assumption that the kinetics of the i.v. dose predict the irreversible disposal of the oral dose. Thus, if irreversible disposal occurred at a greater rate than that predicted, absorption would be under-estimated. However, our data are similar to those previously published with the exception of the Olson et al. (2002) which suggested slower rates of disposal, and that would lead, in our model, to lower estimates of absorption.
In summary, our experiments using stable isotope tracers resolve the kinetics of vitamin K 1 uptake into two exponential functions, an initial fast component followed by a second slower component. This finding supports earlier work using radioactive tracers. The kinetic analysis suggests there may be other, additional body pools with slow exchange that we could not observe in our experiments. By applying postabsorptive kinetics determined from the i.v. dose, we were able to model the percent absorption of an oral vitamin K 1 dose. This work provides a tool for the further investigation of vitamin K 1 absorption and kinetics.
